Lycia Therapeutics

Lycia Therapeutics is a South San Francisco, California biotechnology company developing a new class of targeted protein degradation medicines built on its proprietary lysosomal targeting chimera (LYTAC) platform, which originated in the Stanford University laboratory of Nobel laureate Carolyn Bertozzi, Ph.D. LYTAC molecules bind a disease-driving extracellular protein and shuttle it into the cell for destruction by the lysosome, allowing Lycia to pursue circulating and membrane-bound proteins that conventional small molecules and antibodies have been unable to drug. The company is led by President and Chief Executive Officer Aetna Wun Trombley, Ph.D., is backed by Versant Ventures, Redmile Group, Venrock, RTW and Blue Owl among others, and has partnered with Eli Lilly and Company to discover and develop LYTAC degraders. Lycia is a privately held, research-stage therapeutics company; it publishes no public developer program, API, or machine-readable API artifacts.

Lycia Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Drug Discovery, and Protein Degradation.

Lycia Therapeutics’ developer surface includes engineering blog and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyTherapeuticsDrug DiscoveryProtein DegradationLife SciencesHealthcarePharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.5/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/lycia-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

WellKnownProbe

WellKnownProbe

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 8

The organization behind the API

Website

About

Blog

BlogRSS

Careers

Investors

Partnering

LinkedIn

Scroll for all 8

Other 3

Properties that don't map to a standard resource type

Team

Team

Technology

Technology

StockMarketplace

StockMarketplace

Source (apis.yml)

aid: lycia-therapeutics
image: https://lyciatx.com/wp-content/uploads/2024/10/lycia-logo.png
name: Lycia Therapeutics
description: Lycia Therapeutics is a South San Francisco, California biotechnology company developing a new class of targeted
  protein degradation medicines built on its proprietary lysosomal targeting chimera (LYTAC) platform, which originated in
  the Stanford University laboratory of Nobel laureate Carolyn Bertozzi, Ph.D. LYTAC molecules bind a disease-driving extracellular
  protein and shuttle it into the cell for destruction by the lysosome, allowing Lycia to pursue circulating and membrane-bound
  proteins that conventional small molecules and antibodies have been unable to drug. The company is led by President and
  Chief Executive Officer Aetna Wun Trombley, Ph.D., is backed by Versant Ventures, Redmile Group, Venrock, RTW and Blue Owl
  among others, and has partnered with Eli Lilly and Company to discover and develop LYTAC degraders. Lycia is a privately
  held, research-stage therapeutics company; it publishes no public developer program, API, or machine-readable API artifacts.
url: https://raw.githubusercontent.com/api-evangelist/lycia-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Therapeutics
- Drug Discovery
- Protein Degradation
- Life Sciences
- Healthcare
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/lycia-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/lycia-therapeutics-llms.txt
- type: WellKnownProbe
  url: well-known/lycia-therapeutics-well-known.yml
- type: Website
  url: https://lyciatx.com/
- type: About
  url: https://lyciatx.com/about/overview/
- type: Blog
  url: https://lyciatx.com/news/
- type: BlogRSS
  url: https://lyciatx.com/feed/
- type: Contact
  url: https://lyciatx.com/contact/
- type: TermsOfService
  url: https://lyciatx.com/terms-of-use/
- type: PrivacyPolicy
  url: https://lyciatx.com/privacy-policy/
- type: Careers
  url: https://lyciatx.com/careers/
- type: Investors
  url: https://lyciatx.com/about/investors/
- type: Team
  url: https://lyciatx.com/about/team/
- type: Technology
  url: https://lyciatx.com/technology/lytac-platform/
- type: Partnering
  url: https://lyciatx.com/about/partnering/
- type: LinkedIn
  url: https://www.linkedin.com/company/lycia-therapeutics
- type: StockMarketplace
  url: https://forgeglobal.com/lycia-therapeutics_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 3
  pass: local-v1